HB 736

Amends GS 90-85.3A to allow a pharmacist to (1) administer drugs and (2) order and perform a CLIA-waived test to assist with clinical decision making relating to the use and monitoring of medications or treat influenza, COVID-19, pharyngitis caused by group A streptococcus and other health conditions screened by the test in accordance with statewide protocols. Prohibits a pharmacist from treating a health condition under GS 90-85.3A with any controlled Schedule I-IV controlled substance. Defines CLIA-waived test as a lab test approved by the FDA and waived under the federal Clinical Laboratory Improvement Amendments of 1988. Effective October 1, 2025.